AlphAIalphai — Financial news for AI agents
investing.comSEP 22 min read$TLX

H.C. Wainwright reiterates Telix Pharmaceuticals stock rating on trial completion

H.C. Wainwright reiterated a Buy rating and $20.00 price target for Telix Pharmaceuticals (TLX) after the company completed enrollment in its Phase 3 BiPASS trial. TLX shares are up 53.9% over six months, trading at $10.85. The trial evaluates Illuccix and Gozellix for prostate cancer detection. Telix also aligned with the FDA on a New Drug Application pathway. The company reported a 22% revenue increase to AUD 477 million for H1 2026, with net profit at AUD 38 million.

Original reporting
investing.com
Published Sep 2, 2026, 12:20 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 3, 2026, 5:44 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefTechnology
Primary signal
$TLX
Bullish
high confidence
Mentioned
$TLX
Relevance
8/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$TLXBullishMed
01

Why it matters

The enrollment milestone removes a key development hurdle, potentially accelerating FDA interactions and market adoption.

02

Market read

Positive trial progress may boost TLX stock and influence related biotech equities.

03

What to watch

Potential competition from other imaging agents and reimbursement uncertainties.

Relevance 8/10Novelty 8/10Timing: today

Background

Telix Pharmaceuticals (NASDAQ:TLX) focuses on precision‑medicine imaging agents for prostate cancer.

Company-level read

Ticker impact

$TLXBullishHigh confidence
Context

Telix completed enrollment of 350 patients in its Phase 3 BiPASS trial, a fresh milestone for the company.

Expected impact

potential price appreciation as investors re‑price the reduced clinical uncertainty

Evidence & confidence

The trial is now fully enrolled, enabling data read‑out sooner; analysts have raised price targets.

Market effects

Sector

strengthens the prostate‑cancer diagnostics niche and may lift peers in biotech

Regional

U.S. biotech sector gains modestly on the news

Global

limited to investors tracking oncology trial pipelines

Counterpoint

What could challenge this read

Enrollment success does not guarantee positive trial outcomes; data read‑out could be negative.

Key entities

  • company
    Telix Pharmaceuticals

    Developer of Illuccix and Gozellix imaging agents.

Read at source← All news

Related articles

SEP 2
$TLXHighAI 8/10

Why is Telix Pharmaceuticals stock rallying today?

Telix Pharmaceuticals (TLX) stock rose 5.2% in pre-market trading after completing patient enrollment in its Phase 3 BiPASS study for prostate cancer detection. The FDA aligned on an NDA pathway, and H.C. Wainwright reiterated a Buy rating with a $20.00 price target. The company reported strong H1 2026 financials, including 22% revenue growth and 146% EBITDA increase.

investing.com2 min
SEP 2
$UPCMed

6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & More

Universe Pharmaceuticals (UPC) rose 34.89% after-hours due to multiple Schedule 13G filings. BioAffinity (BIAF) explores new uses for its CyPath Lung test, up 3%. Modular Medical (MODD) gained 7% after announcing a product launch. MAIA (MAIA) rose 6% following an insider purchase. Telix (TLX) completed a Phase 3 study, up 2.21%. aTyr Pharma (ATYR) awaits FDA response, up 4%.

rttnews.com2 min
SEP 2
$TLXMedAI 8/10

Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway

Telix Pharmaceuticals has completed patient enrollment in its Phase 3 BiPASS study for prostate cancer imaging agents Illuccix and Gozellix. The company has aligned with the FDA on an NDA pathway, which, if approved, could support reimbursement and broaden patient access. The study aims to evaluate the diagnostic performance of 68Ga-PSMA-PET combined with MRI for detecting prostate cancer prior to biopsy, potentially reducing unnecessary procedures.

daily-tribune.com2 min
AUG 21
$TLXMedAI 8/10

Telix Pharmaceuticals H1 Earnings Call Highlights

Telix Pharmaceuticals reported H1 earnings, with precision medicine EBITDA up 26% YoY to AUD 132M. Telix Manufacturing Solutions revenue rose 10% YoY to AUD 89M, while internal revenue via RLS increased 70% to AUD 57M. The company's PSMA imaging portfolio revenue grew 9% sequentially to $202M. Telix is investing in manufacturing and distribution capacity and has regulatory updates for Pixclara and Zircaix. The BiPASS study is nearing enrollment completion, potentially doubling the PSMA imaging m

yahoo.com2 min